
Thomas Allen Gardner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2454037/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nuclear Factor.κB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research, 2004, 10, 5501-5507.	7.0	157
2	Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Human Vaccines and Immunotherapeutics, 2012, 8, 534-539.	3.3	85
3	Early Catheter Removal After Radical Retropubic Prostatectomy: Long-term Followup. Journal of Urology, 2003, 169, 2170-2172.	0.4	51
4	Phase I/II Trial of High Intensity Focused Ultrasound for the Treatment of Previously Untreated Localized Prostate Cancer. Journal of Urology, 2007, 178, 2366-2371.	0.4	36
5	NFATc1 with AP-3 Site Binding Specificity Mediates Gene Expression of Prostate-specific-membrane-antigen. Journal of Molecular Biology, 2003, 330, 749-760.	4.2	32
6	Evaluation of Hydrogel Tissue Sealant in Porcine Laparoscopic Partial-Nephrectomy Model. Journal of Endourology, 2005, 19, 1122-1126.	2.1	32
7	Nephrectomy for metastatic renal cell carcinoma: Indiana University experience. Urology, 2003, 62, 636-640.	1.0	21
8	Targeting Prostate Cancer with Conditionally Replicative Adenovirus Using PSMA Enhancer. Molecular Therapy, 2004, 10, 1051-1058.	8.2	18
9	Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. Nuclear Medicine and Biology, 2017, 46, 32-35.	0.6	18
10	ACCURACY OF PREDICTING LONG-TERM PROSTATE SPECIFIC ANTIGEN OUTCOME BASED ON EARLY PROSTATE SPECIFIC ANTIGEN RECURRENCE RESULTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2001, 166, 2198-2201.	0.4	15
11	Utility of the fourth arm to facilitate robot-assisted laparoscopic radical prostatectomy. BJU International, 2005, 95, 183-186.	2.5	14
12	Fas-Fas ligand signaling pathway mediates an interleukin-12-induced rejection of a murine prostate tumor system. Prostate, 2002, 53, 69-76.	2.3	6
13	Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 370.e21-370.e25.	1.6	6
14	Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2012, 30, 4650-4650.	1.6	3
15	Editorial Comment. Urology, 2015, 86, 319-320.	1.0	0